TITLE

Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers

AUTHOR(S)
Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee
PUB. DATE
May 2014
SOURCE
Yonsei Medical Journal;May2014, Vol. 55 Issue 3, p683
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thiol metabolite. CYP3A4 is involved in the metabolism of both clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports have suggested an inhibitory interaction between CCBs and clopidogrel. Accordingly, the aim of this study was to determine the effect of CCBs on the antiplatelet activity of clopidogrel by serial P2Y12 reaction unit (PRU) measurements. Materials and Methods: We assessed changes in antiplatelet activity in patients receiving both clopidogrel and CCBs for at least 2 months prior to enrollment in the study. The antiplatelet activity of clopidogrel was measured by VerifyNow P2Y12 assay in the same patient while medicated with CCBs and at 8 weeks after discontinuation of CCBs. After discontinuation of the CCBs, angiotensin receptor blockers were newly administered to the patients or dosed up for control of blood pressure. Results: Thirty patients finished this study. PRU significantly decreased after discontinuation of CCBs (238.1±74.1 vs. 215.0±69.3; p=0.001). Of the 11 patients with high post-treatment platelet reactivity to clopidogrel (PRU=275), PRU decreased in nine patients, decreasing below the cut-off value in seven of these nine patients after 8 weeks. Decrease in PRU was not related to CYP2C19 genotype. Conclusion: CCBs inhibit the antiplatelet activity of clopidogrel.
ACCESSION #
95641814

 

Related Articles

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Primary Care Reports;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Oncology Alert;Nov2009 Supplement, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Neurology Alert;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Scott, S. A.; Sangkuhl, K.; Gardner, E. E.; Stein, C. M.; Hulot, J.-S.; Johnson, J. A.; Roden, D. M.; Klein, T. E.; Shuldiner, A. R. // Clinical Pharmacology & Therapeutics;Aug2011, Vol. 90 Issue 2, p328 

    The article discusses the implementation of consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. It mentions the aim of the guidelines which is to provide information regarding the clinical use of CYP2C19 genotype test results in patients requiring...

  • The role of genetic factors in clopidogrel antiplatelet therapy. Cieślewicz, Artur Robert; Kaźmierczak, Ewa; Jabłecka, Anna // Advances in Interventional Cardiology;2012, Vol. 8 Issue 2, p126 

    Thienopyridine derivative antiplatelet agents play an important role in the treatment of coronary artery disease. Clopidogrel is a drug blocking action of the platelet ADP receptor (P2Y12). It is applied in the form of a prodrug that requires metabolic activation by cytochrome P450 enzymes. The...

  • Clopidogrel and aspirin. Elliott, William T. // Neurology Alert;Jun2010 Primary Care, Vol. 15 Issue 6, p2 

    The article highlights a study which looked at the effectiveness of dual antiplatelet therapy with clopidogrel and aspirin in patients with drug-eluting stents.

  • Implementation of a pharmacogenomics service in a community pharmacy. Ferreri, Stefanie P.; Greco, Angelo J.; Michaels, Natasha M.; O'Connor, Shanna K.; Chater, Rebecca W.; Viera, Anthony J.; Faruki, Hawazin; McLeod, Howard L.; Roederer, Mary W. // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2014, Vol. 54 Issue 2, p172 

    Objective: To determine the feasibility of implementing a pharmacogenomics service in a community pharmacy. Setting: A single community pharmacy that is part of a regional chain known for offering innovative pharmacy services. Practice description: Community pharmacists at the project site...

  • Clopidogrel and aspirin.  // Primary Care Reports;Jun2010 Pharmacology, p2 

    The article discusses a study on the efficacy of antiplatelet therapy with clopdigrel and aspiring in patients with drug-eluting stents.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics